An Experimental Drug That Can Protect Cells From HIV in Three Different Ways

March/April 2016

The pharmaceutical company ViiV Healthcare has bought an unusual compound nicknamed combinectin. This drug was developed by another company called Bristol-Myers Squibb (BMS) and was designed to interfere with HIV's ability to enter cells in three different and complex ways. Most of these involve impairing HIV's ability to interact with key molecules on the surface of cells of the immune system. Combinectin (code named BMS-986197) has a protein molecule attached that helps it to resist being broken down.

Animal experiments suggest that combinectin has similar potency to standard triple anti-HIV therapy.

Researchers expect that combinectin may need to be injected once weekly, just under the skin, in monkeys and humans.

As ViiV has only recently bought this compound (along with a suite of different experimental anti-HIV drugs from BMS), it may take several months for the corporation to prioritize the research and development plans for this and other drugs. Until those plans are completed, we will not know the development timeline for this unique drug.


Krystal M, Wensel D, Sun Y, et al. HIV-1 combinectin BMS-986197: a long-acting inhibitor with multiple modes of action. Conference on Retroviruses and Opportunistic Infections, 22-25 February 2016, Boston, MA. Abstract 97.

This article was provided by Canadian AIDS Treatment Information Exchange. It is a part of the publication TreatmentUpdate. Visit CATIE's Web site to find out more about their activities, publications and services.

No comments have been made.

Add Your Comment:
(Please note: Your name and comment will be public, and may even show up in
Internet search results. Be careful when providing personal information! Before
adding your comment, please read's Comment Policy.)

Your Name:

Your Location:

(ex: San Francisco, CA)

Your Comment:

Characters remaining:


The content on this page is free of advertiser influence and was produced by our editorial team. See our content and advertising policies.